Search
Diloxanide
go.drugbank.com/drugs/DB08792ExperimentalDiloxanide (as [Diloxanide furoate]) is an anti-protozoal drug used in the treatment of Entamoeba histolytica and some other protozoal infections. … Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990.
Laromustine
go.drugbank.com/drugs/DB05817InvestigationalVNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
Gepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigational[L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients.
Dalteparin
go.drugbank.com/drugs/DB06779ApprovedInvestigationalDalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains ...
Piclidenoson
go.drugbank.com/drugs/DB05511InvestigationalCF101 is supplied as an oral drug and has an excellent safety profile. … It is also being considered for the treatment of other autoimmune-inflammatory disorders, such as Crohn's disease, psorasis and dry eye syndrome.
S-8510
go.drugbank.com/drugs/DB06504ExperimentalIt was being codeveloped by Shionogi and GlaxoSmithKline.
Miocamycin
go.drugbank.com/drugs/DB13287Approvedor as an alternative to erythromycin treatment [A176170]. … This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia [L5737].
Icaridin
go.drugbank.com/drugs/DB14074InvestigationalIcaridin has been commonly used as a topically-applied insect repellent in various countries but was officially licensed for use in the United States in 2001 and Canada in 2012 [L4595]. … Icaridin was synthesized by Bayer in the 1980s based on molecular modeling [L4595].
Saquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … [A214382] While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%),[L3450] its current indications require the co-administration of ritonavir - a potent enzyme
Products: Invirase - Cap 200mg, BIOQUINAVIR ® CAPSULAS 200MGAlaproclate
go.drugbank.com/drugs/DB13233ExperimentalAlaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. … Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.